Definium Therapeutics Inc. Publishes Corporate Presentation on DT120 ODT Phase 3 Programs for GAD and MDD

Reuters02-27

<a href="https://laohu8.com/S/DFTX">Definium Therapeutics</a> Inc. Publishes Corporate Presentation on DT120 ODT Phase 3 Programs for GAD and MDD

Definium Therapeutics Inc. released a corporate presentation outlining its strategic focus on generalized anxiety disorder and major depressive disorder and highlighting its late-stage pipeline led by DT120 ODT, an orally disintegrating tablet formulation of lysergide tartrate. The company said DT120 ODT is being evaluated in four Phase 3 studies, with three Phase 3 topline readouts anticipated in 2026, including two pivotal generalized anxiety disorder trials with a primary endpoint of HAM-A at Week 12 and a pivotal major depressive disorder trial with a primary endpoint of MADRS at Week 6. Definium also reported cash, cash equivalents and investments of $411.6 million as of Dec. 31, 2025, with expected runway into 2028. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614079000?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 05:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614079000","market":"nz","top_or_hot":-1,"title":"Definium Therapeutics Inc. Publishes Corporate Presentation on DT120 ODT Phase 3 Programs for GAD and MDD","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DFTX\">Definium Therapeutics</a> Inc. Publishes Corporate Presentation on DT120 ODT Phase 3 Programs for GAD and MDD\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Definium <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. released a corporate presentation outlining its strategic focus on generalized anxiety disorder and major depressive disorder and highlighting its late-stage pipeline led by DT120 ODT, an orally disintegrating tablet formulation of lysergide tartrate. The company said DT120 ODT is being evaluated in four Phase 3 studies, with three Phase 3 topline readouts anticipated in 2026, including two pivotal generalized anxiety disorder trials with a primary endpoint of HAM-A at Week 12 and a pivotal major depressive disorder trial with a primary endpoint of MADRS at Week 6. Definium also reported cash, cash equivalents and investments of $411.6 million as of Dec. 31, 2025, with expected runway into 2028. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Definium Therapeutics Inc. Publishes Corporate Presentation on DT120 ODT Phase 3 Programs for GAD and MDD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDefinium Therapeutics Inc. Publishes Corporate Presentation on DT120 ODT Phase 3 Programs for GAD and MDD\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-27 05:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DFTX\">Definium Therapeutics</a> Inc. Publishes Corporate Presentation on DT120 ODT Phase 3 Programs for GAD and MDD\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Definium <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. released a corporate presentation outlining its strategic focus on generalized anxiety disorder and major depressive disorder and highlighting its late-stage pipeline led by DT120 ODT, an orally disintegrating tablet formulation of lysergide tartrate. The company said DT120 ODT is being evaluated in four Phase 3 studies, with three Phase 3 topline readouts anticipated in 2026, including two pivotal generalized anxiety disorder trials with a primary endpoint of HAM-A at Week 12 and a pivotal major depressive disorder trial with a primary endpoint of MADRS at Week 6. Definium also reported cash, cash equivalents and investments of $411.6 million as of Dec. 31, 2025, with expected runway into 2028. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL4Bs3Mh:1","article_id":"2614079000","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614079000","pubTimestamp":1772141769,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Definium Therapeutics Inc. released a corporate presentation outlining its strategic focus on generalized anxiety disorder and major depressive disorder and highlighting its late-stage pipeline led by DT120 ODT, an orally disintegrating tablet formulation of lysergide tartrate. The company said DT120 ODT is being evaluated in four Phase 3 studies, with three Phase 3 topline readouts anticipated in 2026, including two pivotal generalized anxiety disorder trials with a primary endpoint of HAM-A at Week 12 and a pivotal major depressive disorder trial with a primary endpoint of MADRS at Week 6. Definium also reported cash, cash equivalents and investments of $411.6 million as of Dec. 31, 2025, with expected runway into 2028. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inform","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","DFTX":"Definium Therapeutics"},"translate_title":"Definium Therapeutics Inc.发布针对GAD和MDD的DT120 ODT 3期项目的公司演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DFTX":0.9},"content_text":"Definium Therapeutics Inc. Publishes Corporate Presentation on DT120 ODT Phase 3 Programs for GAD and MDD\n    \n\n        Definium Therapeutics Inc. released a corporate presentation outlining its strategic focus on generalized anxiety disorder and major depressive disorder and highlighting its late-stage pipeline led by DT120 ODT, an orally disintegrating tablet formulation of lysergide tartrate. The company said DT120 ODT is being evaluated in four Phase 3 studies, with three Phase 3 topline readouts anticipated in 2026, including two pivotal generalized anxiety disorder trials with a primary endpoint of HAM-A at Week 12 and a pivotal major depressive disorder trial with a primary endpoint of MADRS at Week 6. Definium also reported cash, cash equivalents and investments of $411.6 million as of Dec. 31, 2025, with expected runway into 2028. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614079000","isCrawlerRequest":true}